Rising cases of cancer and high incidence of a number of metabolic
diseases propel the global Peptide
Therapeutics Market. Other industry drivers are prevalence of lifestyle
diseases, introduction of hybrid methods of peptides synthesis, growing global
population, and improved healthcare infrastructure. A molecule containing two
or more amino acids is known as a peptide. Therapeutic peptides are short amino
acid monomer chains.
Peptides are commonly known as amide bonds. These are used to treat
blood-based disorders, certain types of cancers, chronic ailments, CNS (central
nervous system) disorders, and cardiovascular & respiratory anomalies.
Growing importance of peptide therapeutics in the pharmaceutical market may
significantly contribute to overall demand during the forecast period (2012 to
2020). However, changing customer needs and lack of regulatory standards hinder
industry progress.
Browse Details of Report @ https://www.hexaresearch.com/research-report/peptide-therapeutics-industry
The worldwide peptide therapeutics market is categorized on the basis of
technologies, applications, routes of administration, products, and regions.
Based on technologies, the segments are HPPS (hybrid phase peptide synthesis),
LPPS (liquid phase peptide synthesis), and SPPS (solid phase peptide
synthesis). Owing to cost effectiveness and user-friendliness, SPPS was the
largest contributor to the overall industry in 2013.On the basis of applications,
the market is divided into respiratory, cancer, anti-infection, pain,
metabolic, cardiovascular, dermatology, renal, gastro intestinal, and others.
In 2013, peptide therapeutics were used extensively in cancer treatment. High
incidence of cancer cases worldwide is expected to fuel this segment till 2020.
According to routes of administration, the industry is segmented into
mucosal, pulmonary, parenteral, oral, and others. “Others” includes nasal and
intradermal. Parenteral held the highest industry share in 2013. Based on
products, the bifurcations are generic and innovative. Innovative peptides
dominated the overall industry in 2013.
As per regions, the global peptide therapeutics market is categorized
into Europe, Asia Pacific, North America, and Rest of the World. North America
leads the global industry because of high per capita expenditure on healthcare,
rising income levels, and improvements in healthcare infrastructure. The region
receives substantial support from the government and also from a number of
NGOs.
Asia Pacific may witness robust growth over the forecast period because
of economic progress, favorable government initiatives, and growing population.
Japan, China, and India are the three key regional drivers of the Asia Pacific
market. Prominent companies operating in the global peptide therapeutics market
are Eli Lilly and Company; Takeda Pharmaceutical Company Ltd.; Amylin
Pharmaceuticals LLC; Bachem Holding AG; and Teva Pharmaceuticals.
Rhythm, a U.S. based biopharmaceutical company dealing in peptide
therapeutics presented the phase 2 clinical trial assessment of setmelanotide
in November 2016. Setmelanotide, a peptide drug, is the company’s
melanocortin-4 receptor agonist that is generally used to treat LepR (leptin
receptor) deficiency obesity. This is a rare genetic anomaly that leads to
unrelenting hyperphagia and severe obesity. According to the company, this
disorder affects nearly two thousand people in the U.S. on an annual basis.
Caused by deficiencies & defects in the MC4 pathway, LepR deficiency
obesity affects people in their early childhood. The MC4 pathway in humans
regulates appetite, energy expenditure, and homeostasis. Setmelanotide’s
efficacy was tested by researchers when it was administered everyday by
subcutaneous injection. Over a period of 22 weeks, a LepR patient lost weight
by almost 20%.
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinical-diagnostics-industry
About Us:
Hexa
Research is a market research and consulting organization, offering industry
reports, custom research and consulting services to a host of key industries
across the globe. We offer comprehensive business intelligence in the form of
industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan
Shaw
Hexa
Research
Felton
Office Plaza
6265
Highway 9
Felton,
California 95018
United
States
Phone:
+1-800-489-3075
Email:
sales@hexaresearch.com
Website
- http://www.hexaresearch.com/
Visit Our
Blog: hexaresearch1.blogspot.com
No comments:
Post a Comment